Here, we describe a patient enrolled in a clinical trial of baricitinib, an oral JAK inhibitor with relative selectivity for JAK1 and JAK2, for CANDLE syndrome who experienced dramatic resolution of his AA. Here, JAK1 is linked to proteosome-associated autoinflammatory syndrome.